Senovax™: cutting-edge immunotherapy for lung cancer

Malignant tumors have a notorious ability to shield themselves from the many things that doctors and scientists throw at them. One of their most powerful shields is senescent cell protection. But, for every shield, there is a penetrating weapon… Read more in Hot Science below.

Even though AI applications are currently one of the hottest markets, the founders invoke connections to longevity to enhance their respective ventures’ investment appeal. Read more in Hot Investments below.

‍

Hot Science

Immorta Bio has announced that its innovative immunotherapy product, SenoVax™, has demonstrated an ability to combat lung cancer by targeting senescent cells that shield these tumors from conventional treatments. In preclinical studies in the non-small cell lung cancer space, SenoVax™ successfully induced “immunity” (this is not an immune response, right?, since this is a preclinical model) against these “protective” cells resulting in tumor regression. Remarkably, these effects were achieved without any additional cancer therapies.

Immorta Bio is now moving forward with the final stages of preclinical development and plans to file for an Investigational New Drug (IND) application soon, aiming to initiate clinical trials for advanced lung cancer patients.

The company is committed to treating age-related diseases and leveraging SenoVax™ in enhancing the body's intrinsic senescent cell clearance processes. Application of SenoVax™ to cancer treatment can not only potentially prove to become an effective oncologic therapeutic, but also has been demonstrating its potency in senolytic life extension applications as well.

‍

Hot Investments

Superpower, a San Francisco-based healthcare platform, attracted a number of institutional and angel investors for its $4 million pre-seed round of funding. The company describes its mission as “to empower every person with personalized, preventative, and performance enhancing healthcare.” Notably their press release has added the word “longevity” to their objectives by stating: “The virtual platform makes it easy for people to access personalized, preventative, and longevity focused medicine.”

It seems like “longevity” has become a major attractor of capital. We, at Immorta Bio, are in the focal point of the longevity therapeutics industry. We also envision our pioneering R&D in cellular rejuvenation and senolytic immunotherapy to become a catalyst for transformative investment opportunities comparable to landmark innovations in other areas of biotechnology.

‍

Longevity Shorts

• Lucy Therapeutics has raised $12.5 million to advance therapies targeting mitochondrial dysfunction in diseases like Alzheimer disease and Parkinson disease.

• Cradle has debuted with $48 million in funding to develop technologies for whole-body reversible cryopreservation, aiming to transform organ preservation and extend treatment possibilities for terminal illnesses.

• Acorn Biolabs, a Toronto-based company, has raised $8 million to advance its service of preserving stem cells from hair follicles for future regenerative treatments.
  

‍

Term of the Day

Senotherapeutics: These are a class of therapeutic agents that target cellular senescence, the process by which cells irreversibly stop dividing and enter a state of permanent growth arrest without undergoing cell death. Senotherapeutics work in two main ways:

1. Senolytics eliminate these harmful cells;

2. Senomorphics keep them in check, potentially improving health and lifespan.

‍

Boris Reznik, PhD
Chairman

‍